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Background: Signs of cardiac transthyretin (TTR)
amyloidosis (ATTR) in patients with echocardiographic
increase in interventricular septal thickness (IVST) are
lacking.
Objectives: To identify clinical and ECG/
echocardiographic signs associated with increased
IVST in ATTR.
Methods: Analysis of patients with baseline
echocardiography in the Transthyretin Amyloidosis
Outcomes Survey (THAOS) registry (N=1682). Patients
were categorised into IVST classes according to the
American Society of Echocardiography classification
adapted to gender (ie, normal, mild, moderate, severe);
then into two combined IVST classes (normal-mild and
moderate-severe).
Results: 425 patients were included: 336 with a TTR
mutation (m-TTR) and 89 with wild-type TTR
(WT-TTR). 72% were men. Median (25th, 75th centile)
age was 62 (45, 72) years. Non-Val30Met and WT-TTR
were frequent in moderate (41% and 35%) and severe
(50% and 33%) IVST classes. Median IVST was 15 mm
(14, 16) (moderate) and 20 mm (18, 22) (severe). In the
combined moderate-severe class, 85% of patients were
≥55 years of age; 81% were men; 86% had blood
pressure <140 mm Hg; and 77% had increased right
ventricle thickness (≥7 mm). Up to 66% of patients had
cardiac sparkling. Systolic dysfunction (left ventricular
ejection fraction <50%), restrictive pattern and low
voltage were less frequent, and observed in 49%, 18%
and 33% of patients, respectively.
Conclusions: Increased IVST, especially in men
≥55 years with normal systolic blood pressure, increase
in right ventricle free wall and valve thicknesses, and
sparkling, should alert practitioners to the possibility of
ATTR. Absence of restrictive pattern and low voltage
should not rule out the suspicion.
Trial registration number: NCT00628745 (clinicaltrials.
gov).
INTRODUCTION
Recently, the European Society of Cardiology
(ESC) published a position statement
concerning hypertrophic cardiomyopathy, to
raise clinicians’ awareness of the possible
spectrum of abnormalities in patients, and
eventually their families, with heart muscle
diseases.1 Cardiac hypertrophy is generally
identified by echocardiography and defined
by an increase in interventricular septal
thickness (IVST) and/or the left ventricular
(LV) posterior wall thickness (PWT), with
different cut-off values according to gender.
This definition has been endorsed in the
2014 ESC guidelines.2–4 However, IVST
KEY QUESTIONS
What is already known about this subject?
▸ Amyloidosis is a result of continuous accumula-
tion of insoluble fibril proteins in the extracellu-
lar matrix in various organs including the heart.
The two major proteins involved in this process
are immunoglobulin light chains (AL) and trans-
thyretin (TTR). Cardiac amyloid infiltration is the
classic form of infiltrative hypertrophic cardio-
myopathy (HCM) and is associated with abnor-
mal increased interventricular septal thickening.
What does this study add?
▸ We investigated and identified the clinical and
echocardiographic signs that should alert
practitioners to the possibility of TTR cardiac
amyloidosis in patients with abnormal increased
IVST. In future, additional research using new
sensitive imaging techniques and including the
other major type of cardiac amyloidosis, that is,
light chain amyloidosis, and other types of
HCM, should be undertaken to identify and val-
idate specific diagnostic markers of the different
types of cardiac amyloidosis.
How might this impact on clinical practice?
▸ Cardiac amyloidosis is of poor prognosis and
should be considered in the differential diagno-
sis of patients with abnormal increased IVST.
When suspected, patients should be referred for
genetic testing and/or other imaging evaluation
(MRI and bone scintigraphy), and/or biopsy ana-
lysis should be identified.
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increase alone cannot provide accurate information con-
cerning the aetiology of heart disease. Hence, there is a
need to develop appropriate diagnostic strategies based
on clues from medical and family histories, physical
examination, and non-invasive investigations such as
ECG and echocardiography. Cardiac hypertrophy is now
defined as a morphological increase in thickness of the
LV wall that results from different conditions: cardiomyo-
cyte hypertrophy or infiltration of either cardiomyocytes
or the extracellular matrix.1 Cardiac transthyretin amyl-
oidosis (ATTR) is a classic form of an infiltrative cardio-
myopathy. It is a progressive lethal disease caused by
continuous accumulation of insoluble TTR fibrils in the
extracellular matrix.5
The hereditary form of ATTR expresses different phe-
notypes involving neuropathy and/or cardiomyopathy.6
More than 100 mutations have been reported.7 The
Val30Met mutation is by far the most frequent mutation
reported to cause ATTR, with two distinguishable forms
depending on the age of onset: early (<50 years) and
late (≥50 years).6 Early-onset Val30Met exhibits neur-
opathy as the major presenting feature and is endemic
in Portugal, Japan and Brazil.6 Late-onset Val30Met
patients exhibit neurological as well as cardiac abnormal-
ities.6 Patients with non-Val30Met mutations were also
reported to have cardiomyopathy and/or neuropathy.8
Wild-type (WT) ATTR, also known as senile systemic
amyloidosis, usually affects the heart and primarily
affects older male patients, with a prevalence of 25–36%
observed in an autopsy series of elderly patients.9
Regardless of the genotype, identifying signs that may
alert clinicians to the presence of ATTR cardiomyopathy
are vital, as typical therapies for heart failure are not
well tolerated; emerging treatments are designed to
prevent progression of amyloid infiltration and progno-
sis is directly related to cardiac dysfunction, and is poor
for later-stage disease.10
Accordingly, the aim of this study was to identify clinical,
echocardiographic and ECG parameters associated with
IVST increase in cardiac ATTR using the largest available
international cohort (the Transthyretin Amyloidosis
Outcomes Survey (THAOS)) on this disease to raise clini-
cian’s awareness of the diagnosis of cardiac ATTR.
MATERIALS AND METHODS
Patient population and data collection
The THAOS registry began enrolling patients in
2007. Details of this registry have been previously
published.11 12
Data were obtained from the information given by the
reporting centres, using a standardised dedicated
website. Data entered into the database included, but
were not limited to, demographics, clinical status,
medical history, type of neuropathy when present, ECG
and echocardiographic data, and TTR genotype.
All the participating clinical sites had received author-
isation from their local ethical committees for use of the
registry. Patients entered in the registry were required to
be ≥18 years of age. Privacy and confidentiality of par-
ticipating individuals were assured and each individual
gave written consent.
Data extraction
By 30 June 2013, THAOS included data on 1682
patients, registered from 17 countries. This study reports
the data of the 425 patients included in THAOS with a
baseline echocardiography and IVST measurement in
the range (3–40 mm), prespecified in the registry. Three
patients with baseline echocardiography data were
excluded due to out-of-range IVST values.
Definition of the interventricular septal thickness and
genotype classifications
Patients were divided according to the IVST classification
set by the American Society of Echocardiography.2 3 As
stated, gender was also taken into consideration to limit
misclassification.2 3 Classification was as follows: normal
IVST group if thickness ≤9 mm in female subjects or
≤10 mm in male subjects; mildly abnormal if ≥10 and
≤12 mm in females, or ≥11 and ≤13 mm in males; mod-
erately abnormal if ≥13 and ≤15 mm in females, or ≥14
and ≤16 mm in males;2 3 and severely abnormal if
≥16 mm in females or ≥17 mm in males.2 In a subse-
quent analysis, the normal/mild groups and moderate/
severe groups were pooled to calculate clinical, ECG and
echocardiographic prevalence signs associated with
marked IVST increase.
Patients were also divided into four categories depend-
ing on ATTR genotype and onset: Val30Met early onset
(<50 years), Val30Met late onset (≥50 years), non-
Val30Met and WT-ATTR.
Definition of ECG and echocardiographic variables
recorded
ECG analysis and measurements included heart rate, PR
interval, QRS duration, QT interval, atrial fibrillation,
pathological Q waves and low voltage. The latter was
defined as QRS voltage amplitude <0.5 mV in all limb
leads or <1 mV in all precordial leads.
Echocardiographic measurements were obtained
in accordance with the American Society of
Echocardiography recommendations. Wall and valve
thickness (IVST; PWT; RV free-wall thickness;
mitral, aortic and tricuspid valvular thickening) as
well as LV and LA size (LV end-diastolic diameter
(LVEDD) and left atrial diameter (LAD)) were mea-
sured on transthoracic echocardiograms. LV ejec-
tion fraction (LVEF) was measured using Simpson’s
biplane method. Peak E and A wave velocities were
measured on Doppler mitral flow. Systolic pulmon-
ary artery pressure (syst PAP) was estimated from
the modified Bernoulli equation.13 Peak Ea velocity
was measured on tissue Doppler images recorded at
the annular mitral valve. Mitral regurgitation (MR)
was quantified by measuring the MR area of the
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colour Doppler signal divided by the left atrial area
measured in the four-chamber view.14 MR was con-
sidered ‘mild or less’ if MR area/LA area was <10%,
‘severe’ if MR area/LA area was >40% and ‘moder-
ate’ if between the two.
Definition of selected clinical, ECG and echocardiographic
classes
Patients were divided according to baseline symp-
toms. Symptoms were defined as ‘any symptom clas-
sified as possibly or definitely related to TTR
amyloidosis as they were recorded in medical
history or general examination in the THAOS regis-
try’. To study the prevalence of potential signs asso-
ciated with cardiac ATTR, clinical, ECG and
echocardiographic characteristics were defined as
follows: advanced age if ≥55 years, high systolic
blood pressure (SBP) if ≥140 mm Hg,15 abnormal
LVEF if <50%,16 hypertrophied posterior wall if
PWT >13 mm for women and ≥14 mm for men,4
asymmetric hypertrophy if IVST/PWT ratio >1.3,17
restrictive filling pattern if E/A transmitral flow vel-
ocities >218 and increased RV free-wall if RV thick-
ness ≥7 mm.19
Statistical analysis
Continuous variables are reported as median, and 25th
and 75th centiles. For nominal qualitative data, n and
percentage were reported. Statistical differences between
patient groups were calculated using χ2 test for categor-
ical variables. For continuous variables, the
Mann-Whitney test was used when two groups were com-
pared and the Kruskal-Wallis test when more than two
groups were compared. Statistical analysis was performed
using SAS software; p<0.05 was considered significant.
RESULTS
Baseline characteristics of the echocardiographic THAOS
subpopulation
The median (25th and 75th centile) age of the study
population of 425 patients was 62 (45, 72) years and
73% were men. Figure 1 presents the flow chart of the
study, and prevalence of men and women, according to
the IVST classification. A total of 336 patients had a diag-
nosis of m-ATTR and 89 of WT-ATTR (table 1).
Val30Met mutation alone accounted for 50% of the
m-ATTR subpopulation, of whom 104 were in early-onset
and 63 were in late-onset groups (table 1).
Clinical, biological and ECG characteristics of the THAOS
echo-subgroup according to the IVST classes
Baseline demographic, genetic, echocardiographic, ECG
and biological parameters with respect to the four IVST
classes, are shown in table 1. Briefly, moderate or severe
IVST was observed more frequently in non-Val30Met
and in WT-TTR amyloidosis. Of the early Val30Met
patient group, 90% had normal or mild increased IVST.
Older age, male gender, cardiac symptoms, history of
heart failure, higher brain natriuretic peptide (BNP)
values, conduction abnormalities, low voltage and patho-
logical Q waves, were more frequent in the moderate
and severe IVST classes. No differences were observed in
body mass index (BMI), modified BMI (mBMI), heart
rate, troponin I and T values, and there was equal preva-
lence of pacemaker implant between the different IVST
classes.
Echocardiographic characteristics of the THAOS
echo-subgroup according to the IVST classes
Baseline echocardiographic data according to the IVST
classification are summarised in table 2. Increased IVST
Figure 1 Study flow chart and IVST classification according to gender . *Prespecified IVST range 3–40 mm (IVST,
interventricular septal thickness; THAOS, Transthyretin Amyloidosis Outcomes Survey).
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severity was associated with higher sparkling, decreased
LVEF, prevalence of moderate to severe MR, valvular
thickening, increased LAD and increased syst PAP. E/A
was significantly different in the four IVST classes, and
was more elevated in patients with normal and severe
IVST. In all groups, the median of E/A was <1.5.
Prevalence of clinical, echocardiographic and ECG
abnormal signs in patients with respect to IVST classes
The prevalence of clinical, echocardiographic and
ECG abnormal signs in patients with moderate and
severe IVST is shown in figure 2. The most frequent
signs (>60%) are dyspnoea (New York Heart
Association (NYHA) II–IV), age >55 years, male
gender, LAD enlargement, increased RV free wall
thickness, LV dysfunction measured by ejection frac-
tion, and myocardial sparkling. IVST/PWT ratio
>1.3, a sign of asymmetric septal hypertrophy
encountered most commonly in sarcomeric cardio-
myopathy, was reported in 21%; whereas low
voltage, believed to be a strong sign of ATTR, was
observed in only a third of these patients.
Detailed comparisons of clinical, echocardiographic
and ECG abnormal signs between the normal-mild IVST
Table 1 Comparison of baseline clinical, biological and ECG variables among patients with normal, mild, moderate and
severe IVST
IVST
Variables N Normal Mild Moderate Severe p Value
N 425 80 93 81 171
Genetic
ATTR FAP early Val30Met, n (%) 104 50 (63) 44 (47) 8 (10) 2 (1) <0.0001*
ATTR FAP late Val30Met, n (%) 63 7 (9) 17 (18) 12 (15) 27 (16)
ATTR FAP non-Val30Met, n (%) 169 22 (28) 29 (31) 33 (41) 85 (50)
Wild type, n (%) 89 1 (1) 3 (3) 28 (35) 57 (33)
Demographic and clinical
Age, years 425 35 (31,50) 49 (39,64) 67 (58, 76) 69 (61, 75) <0.0001
Male, n (%) 425 52 (65) 55 (59) 62 (77) 143 (84) <0.0001
Pacemaker, n (%) 221 2 (12) 6 (21) 12 (24) 35 (28) 0.4524
Myocardial infarction, n (%) 421 0 (0) 0 (0) 2 (3) 3 (2) 0.3007
Heart failure, n (%) 421 8 (10) 16 (18) 45 (56) 124 (73) <0.0001
Palpitations, n (%) 421 6 (8) 5 (6) 11 (14) 32 (19) 0.0081
Syncope, n (%) 421 5 (6) 5 (6) 12 (15) 32 (19) 0.0044
BMI, kg/m2 376 24 (21,26) 24 (22,27) 25 (22,27) 25 (23,27) 0.4255
Karnofsky index, % 360 90 (80,90) 90 (80,90) 80 (70,90) 75 (60,80) <0.0001
NYHA II–IV vs I, n (%) 190 6 (75)† 12 (75) 40 (89) 112 (93) 0.0866
SBP, mm Hg 374 121 (110,130) 122 (114,132) 120 (105,130) 112 (104,130) 0.0025
DBP, mm Hg 374 77 (70,84) 78 (71,83) 70 (66,80) 70 (65,80) 0.0002
Age at onset, years 423 31 (27,44) 43 (33,57) 60 (49,70) 62 (53,70) <0.0001
Liver transplant, n (%) 425 16 (20) 11 (12) 11 (14) 12 (7) 0.0268
Age at liver transplant, years 50 40 (35,52) 44 (32,54) 55 (48,61) 50 (39,60) 0.0675
Motor neuropathy, n (%) 425 31 (39) 33 (36) 33 (41) 69 (40) 0.8688
Sensory neuropathy, n (%) 425 69 (86) 79 (85) 54 (67) 92 (54) <0.0001
Autonomic neuropathy, n (%) 425 59 (74) 59 (63) 45 (56) 98 (57) 0.0529
Biological
BNP, pg/mL 141 32 (14,83) 72 (37,179) 591 (206,1027) 552 (216,939) 0.0031
NT-proBNP, pg/mL 152 55 (27,108) 100 (47,649) 939 (330,3445) 3507 (1658,8982) 0.4320
Troponin I, ng/mL 37 0.06 (0.06,0.06) 0.06 (0.02,0.1) 0.06 (0.02,0.09) 0.12 (0.07,0.15) 0.1329
Troponin T, ng/mL 122 0.01 (0.01,5) 0.01 (0.01,0.04) 0.04 (0.02,0.06) 0.05 (0.03,0.08) 0.1828
ECG
Heart rate, bpm 349 74 (68, 85) 74 (65, 78) 72 (64, 82) 74 (65,85) 0.6633
PR interval, ms 236 166 (148,188) 161 (149,200) 178 (152,208) 193 (176,220) 0.0011
QRS interval, ms 294 94 (86,100) 98 (88,106) 110 (88,126) 116 (100,148) <0.0001
QT interval, ms 280 378 (360,397) 394 (361,413) 424 (390,461) 438 (398,470) <0.0001
Low voltage, n (%) 265 2 (4) 5 (9) 20 (39) 34 (30) <0.0001
Pathologic Q waves, n (%) 229 3 (17) 2 (7) 17 (31) 51 (41) 0.0013
*Only TTR FAP was included in the analysis (wild type excluded).
†Data for this parameter were not reported in 90% of the patients of this group. Continuous variables are presented as median (25th, 75th
centile). Percentage indicates proportion of patients with the variable within each IVST category.
ATTR, transthyretin amyloidosis; BMI, body mass index; BNP, brain natriuretic peptide; DBP, diastolic blood pressure; FAP, familial amyloid
polyneuropathy; IVST, interventricular septal thickness; NT-proBNP, N-terminal proBNP; NYHA, New York Heart Association; SBP, systolic
blood pressure.
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and moderate-severe IVST groups are shown in table 3.
Briefly, patients with moderate to severe IVST were
older, more symptomatic, male gender, and presented
low voltage and Q waves, LV systolic dysfunction,
increased filling pressure (Ea >15), and left atrial
enlargement, and had more myocardial sparkling and
valvular thickening, and increased RV wall and PWTs,
than normal to mild IVST patients.
Table 2 Comparison of baseline echocardiographic characteristics among patients according to IVST classification
IVST
N Normal Mild Moderate Severe p Value
IVST, mm 425 9 (8, 10) 11 (10, 12) 15 (14, 16) 20 (18, 22) –
PWT, mm 403 9 (8, 9) 10 (9, 11) 14 (12, 15) 18 (16, 20) <0.0001
LVEDD, mm 379 45 (42, 48) 46 (42, 49) 45 (41, 48) 43 (39, 47) 0.0129
Sparkling, n (%) 299 17 (33) 23 (38) 30 (53) 93 (72) <0.0001
LVEF, % 327 62 (56, 70) 60 (55, 67) 55 (45, 60) 43 (35, 60) <0.0001
RV wall thickness, mm 87 6 (5, 7) 6 (5, 7) 8 (6, 9) 9 (7, 10) 0.0086
Mitral thickening, n (%) 228 5 (14) 4 (9) 14 (33) 51 (48) <0.0001
Aortic thickening, n (%) 225 6 (16) 9 (21) 12 (29) 42 (40) 0.0184
Tricuspid thickening, n (%) 221 0 (0) 2 (5) 2 (5) 18 (18) 0.0031
LAD, mm 359 33 (30, 35) 36 (33, 40) 42 (39, 46) 45 (42, 49) <0.0001
Syst PAP, mm Hg 140 24 (19, 25) 25 (20,28) 30 (26, 40) 40 (30,45) <0.0001
E, cm/s 139 74 (62, 85) 70 (63, 81) 88 (65, 102) 81 (67, 101) 0.0107
A, cm/s 114 54 (48, 65) 64 (56, 75) 70 (56, 104) 54 (40, 81) 0.0048
E/A 109 1.3 (1, 1.7) 1.1 (0.9, 1.2) 0.9 (0.7, 1.6) 1.3 (0.9, 2.4) 0.0390
E/Ea, mean±SD 60 7.3±4.0 7.8±4.3 14.4±6.7 16.8±6.7 0.0001
Continuous variables are presented as median (25th, 75th percentile). Percentage indicates proportion of the patients with the variable within
each IVST category.
IVST, interventricular septal thickness; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection
fraction; PWT, posterior wall thickness; RV, right ventricle; syst PAP, systolic pulmonary arterial pressure.
Figure 2 Prevalence of the clinical, ECG and echocardiographic signs in the group with moderate and severe IVST increase in
the THAOS population with echocardiography data available at baseline (N=252). *Women >13 mm, men >14 mm (IVST,
interventricular septal thickness; n, number of patients with individual sign; N, number of patients with evaluations available for
individual sign; NYHA, New York Heart Association; PWT, posterior wall thickness, RV, right ventricle; SBP, systolic blood
pressure; THAOS, Transthyretin Amyloidosis Outcomes Survey).
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Prevalence of clinical, echocardiographic and ECG
abnormal signs in the moderate and severe group,
according to genotype and disease onset
Of the overall early-onset and late-onset Val30Met,
non-Val30Met and WT-ATTR, 10%, 62%, 70% and 96%,
had moderate or severe IVST, respectively. Percentages
of signs depending on genotype and/or disease onset
for Val30Met in the moderate to severe IVST group are
presented in table 4. Briefly, the prevalence of age
≥55 years and male gender were higher in the WT
versus other ATTR groups (table 4). Neuropathy was
more frequent in late Val30Met compared with
non-Val30Met and WT patients. Hypertension or asym-
metric ‘hypertrophy’ was more frequently observed in
late Val30Met than in patients with non-Val30Met and
WT-ATTR. Prevalence of dyspnoea, Q waves, left atrial
dilation and sparkling was similar in the late Val30Met,
non-Val30Met and WT-ATTR groups (table 4). However,
it is important to note that no specific clinical, ECG or
echocardiographic signs were exclusively associated with
a given ATTR genotype.
DISCUSSION
This study identified clinical, ECG and echocardio-
graphic features that should alert cardiologists to suspect
amyloidosis in patients with increased IVST, using the
THAOS registry.
First, we demonstrated that advanced age, male
gender, dyspnoea, increased RV free-wall thickness and
echocardiographic myocardial sparkling, were frequently
associated with moderate to severe IVST in patients with
mostly normal SBP <140 mm Hg. Second, we showed
that asymmetric LV ‘hypertrophy’ and absence of trans-
mitral restrictive pattern or low voltage should not rule
out a diagnosis of ATTR in these patients; and third, we
pointed out that these methods could not discriminate
the different TTR genotypes.
Interest of a large international registry
The THAOS registry represents the largest available
database to document transversal ATTR characteristics
and offers the unique opportunity to analyse data
according to different genotypes and phenotypes. The
international nature of the study allows for the general-
isation of the findings, as it includes data from various
countries and centres. A further advantage of such a
large database is the use of standardised forms and the
uniform manner in which data from a large number of
patients with different genotypes are collected.
IVST measured by echocardiography as a useful tool to
screen symptomatic patients for ATTR
Increased wall thickness of the heart is frequently diag-
nosed by echocardiography in patients; however, it could
result from a number of different conditions. Progress








Age ≥55 years, n (%) 425 56 (32) 214 (85) <0.0001
NYHA II–IV, n (%) 190 18 (75) 152 (92) 0.0134
Male, n (%) 425 107 (62) 205 (81) <0.0001
SBP ≥140 mm Hg, n (%) 374 19 (12) 30 (14) 0.7141
Sensory neuropathy, n (%) 425 148 (86) 146 (58) <0.0001
Motor neuropathy, n (%) 425 64 (37) 102 (41) 0.4698
ECG
Low voltage, n (%) 265 7 (7) 54 (33) <0.0001
Q waves, n (%) 229 5 (10) 68 (38) 0.0002
Echo
LVEF <50%, n (%) 327 18 (14) 98 (49) <0.0001
Posterior wall moderate or severe
hypertrophy (women ≥13 mm, men ≥14 mm), n (%)
403 0 (0) 165 (69) <0.0001
IVST/PWT ratio >1.3, n (%) 403 11 (7) 49 (21) 0.0001
E/A >2, n (%) 109 5 (7) 7 (18) 0.0705
E/Ea mean >15, n (%) 60 4 (8) 4 (40) 0.0066
RV free wall thickness ≥7 mm, n (%) 87 20 (42) 30 (77) 0.0009
LAD >40 mm, n (%) 359 26 (18) 171 (79) <0.0001
Sparkling, n (%) 299 40 (36) 123 (66) <0.0001
Aortic thickening, n (%) 225 15 (19) 54 (37) 0.0052
Mitral thickening, n (%) 228 9 (11) 65 (44) <0.0001
Tricuspid thickening, n (%) 221 2 (3) 20 (14) 0.0053
IVST, interventricular septal thickness; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association;
PWT, posterior wall thickness; RV, right ventricle; SBP, systolic blood pressure.
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in molecular biology has elucidated the underlying
genetic abnormalities in many cases of cardiac hyper-
trophy; however, in daily practice, cardiologists have
access first to the phenotype of patients rather than its
genetic defects. As was pointed out in the recent ESC
statement concerning hypertrophic cardiomyopathy,
there is still a need to develop appropriate diagnostic
strategies based on clues from medical and family histor-
ies, physical examination and non-invasive investigations
such as echocardiography.1 Hence, identification of clin-
ical signs associated with specific genetic disease, such as
ATTR, is an important step before performing appropri-
ate genetic testing.
Clinical and echocardiographic signs associated with
increased IVST in ATTR
In the present study, we identified signs that may provide
guidance in a possible diagnosis of ATTR. We demon-
strated that age >55 years and male gender are fre-
quently associated with increased IVST ≥13 mm in
female, and ≥14 mm in male patients with ATTR.
WT-ATTR, non-Val30Met and late-onset Val30Met
patients showed higher IVST than early Val30Met
patients. This may be explained by the relationship
between increased IVST and age, and male gender, as
shown in a previous study.16 Accordingly, in our study,
WT-ATTR, non-Val30Met and late-onset Val30Met
patients were older, and more frequently male, than
early Val30Met patients. However, mechanisms other
than age and gender might be involved in IVST
increase, such as TTR fibril composition. Unfortunately,
this information is lacking in the THAOS registry.
Late-onset Val30Met and WT-ATTR showed fragmented
TTR protein; conversely, whole TTR protein is observed
in early-onset Val30Met.20 21
The striking difference in penetrance according to
gender has been reported in several previous
studies.22 23 Of note, 94% of patients with WT-ATTR
were men; which is in accordance with reports in the lit-
erature.24–26 In Val30Met, as described previously,22 male
gender dominated among late-onset patients compared
to those with early onset. To the best of our knowledge,
no pathophysiological explanation for this gender dis-
crepancy has emerged.
In our study, most patients with increased IVST had
normal blood pressure and dyspnoea. Hypertension
is a ubiquitous cause of LV hypertrophy, with
advanced age. Therefore, the combination of
increased IVST and normal blood pressure should
increase cardiologists’ awareness of the possibility of
cardiac amyloidosis. Conversely, in daily practice, dys-
pnoea might not be useful to discriminate ATTR
amyloidosis from other hypertrophic cardiomyop-
athies. Of course, these signs are also frequent in







Late onset non-Val30Met WT
N 10 39 118 85
Clinical
Age ≥55 years, n (%) 5 (50) 39 (100) 85 (72) 85 (100)
NYHA II–IV, n (%) 2 (100) 13 (87) 65 (93) 72 (91)
Gender, male, n (%) 6 (60) 31 (80) 88 (75) 80 (94)
SBP ≥140 mm Hg, n (%) 3 (33) 13 (37) 8 (8) 6 (8)
Sensory neuropathy, n (%) 9 (90) 37 (95) 75 (64) 25 (29)
Motor neuropathy, n (%) 8 (80) 30 (77) 57 (48) 7 (8)
ECG
Low voltage, n (%) 1 (17) 2 (11) 27 (38) 24 (35)
Q waves, n (%) 1 (17) 8 (44) 31 (38) 28 (38)
Echocardiography
LVEF <50%, n (%) 0 (0) 2 (15) 53 (51) 43 (55)
Posterior wall hypertrophy*, n (%) 1 (10) 17 (53) 80 (71) 67 (79)
IVST/PWT ratio> 1.3, n (%) 3 (30) 13 (41) 23 (21) 10 (12)
E/A >2, n (%) 0 (0) 1 (20) 3 (14) 3 (30)
E/Ea mean >15, n (%) 0 (0) NA 3 (75) 1 (25)
RV free wall thickness ≥7 mm, n (%) 1 (33) 7 (88) 14 (74) 8 (89)
LAD >40 mm, n (%) 5 (56) 28 (80) 69 (73) 69 (89)
Sparkling, n (%) 4 (67) 25 (74) 56 (65) 38 (62)
Aortic thickening, n (%) 1 (33) 2 (18) 33 (46) 18 (30)
Mitral thickening, n (%) 0 (0) 2 (18) 37 (51) 26 (43)
Tricuspid thickening, n (%) NA 1 (9) 12 (17) 7 (12)
*Moderate or severe hypertrophy=women >13 mm and men >14 mm; NA, no data available for tricuspid valve thickening in early-onset
Val30Met and for E/Ea in late onset for Val30Met.
IVST, interventricular septal thickness; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association;
PWT, posterior wall thickness; RV, right ventricle; SBP, systolic blood pressure.
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amyloid light-chain (AL) amyloidosis, and this diag-
nosis should be ruled out by identification of amyloi-
dogenic monoclonal proteins (serum and urine
immunofixation combined with free light-chain quan-
tification) and demonstration of TTR amyloid depos-
ition in a tissue specimen.
Increased RV wall thickness, valvular thickening and
granular sparkling of the myocardium were frequently
observed in patients with moderate to severe IVST, in
accordance with previous findings.25 27 28 TTR infiltrates
all the structures of the heart (left and right ventricle
(RV) and valves) in contrast to hypertension, which only
increases LV wall thickness.29 Increases in aortic valve
and mitral valve thickening were frequently observed. In
previous studies, atrioventricular thickening has been
proposed as a marker for cardiac amyloidosis.28 Rapezzi
et al30 showed recently that half of patients with ATTR
exhibited abnormal valvular thickness whereas only 3%
exhibited sarcomeric hypertrophic cardiomyopathies.
Myocardial sparkling, a qualitative—but subjective and
highly dependent on the echocardiographic technique
(harmonic)—sign of amyloid infiltration, was observed
in 65% of the patients with moderate to severe IVST in
our study, which is in agreement with previous
reports.31–33 Combination of increased RV wall thick-
ness, valvular thickening and sparkling, are of particular
relevance to the diagnosis of ATTR in patients with
increased IVST. However, increased RV wall thickness
can also be observed in cases of symmetric LV hyper-
trophy in Fabry disease or in mitochondrial cytopathy,
and in cases of asymmetric LV hypertrophy in sarco-
meric hypertrophic cardiomyopathy. Thus it is more the
combination of signs rather than the sign alone that
may suggest a diagnosis of TTR amyloidosis.
Absence of signs should not rule out the diagnosis
Cardiac amyloidosis is often described as a restrictive
cardiomyopathy with symmetric hypertrophic pattern,
preserved ejection fraction and ECG low voltage.5 34
In our study, the restrictive transmitral pattern was
observed in only 18% of patients with ATTR moderate
to severe IVST. Asymmetric LV hypertrophy pattern was
not rare, as it was exhibited in 21% of patients with mod-
erate and severe IVST. This asymmetric pattern was
more frequently observed in late-onset Val30Met and in
non-Val30Met than in WT-ATTR. Forty-nine per cent of
patients with moderate to severe IVST had an ejection
fraction <50%. Low voltage was observed in less than
one-third of the patients. All of this suggests that
absence of a restrictive pattern or low voltage, or pres-
ence of asymmetric hypertrophy pattern or LV systolic
dysfunction, should not rule out the diagnosis of ATTR
amyloidosis.
Study limitations
There are several limitations in investigations based on
data collected in observational surveys such as THAOS.
As data were collected during routine clinical practice
from many centres/countries and at the discretion of
the patient’s physician, there are inevitably variations in
the type of clinical investigations conducted. In particu-
lar, at the time when these data were reviewed (data
cut-off date 30 June 2013), echocardiography was not
considered as a routine clinical examination in many
participating neurology centres. Thus, patients with pri-
marily neurological manifestations of their disease are
generally attended by neurologists and do not undergo
heart examinations to a similar extent as those present-
ing with primarily heart problems and followed by cardi-
ologists. Thus, there was a selection bias in investigations
performed, with heart examinations rarely performed in
patients with early-onset ATTR Val30Met disease. The
high prevalence of heart failure (NYHA II–IV) noted in
the group of patients with normal-mild increased IVST
probably represents a selection bias, where patients with
symptoms of dyspnoea are registered as having heart
failure and undergo echocardiographic examination.
Similarly, heart examinations are generally not carried
out on asymptomatic carriers of an ATTR gene muta-
tion, a group that otherwise would be interesting to
analyse. Furthermore, the conclusion of this study may
be applicable only for patients with the same character-
istics as those included in this study.
Non-Val30Met includes many different mutations with
phenotype heterogeneity that could not be addressed in
this study due to the limited number of patients with
echocardiography.
Echocardiographic measurements such as MR meas-
urement by vena-contracta or proximal isovelocity
surface area, or new echocardiographic techniques such
as strain or strain rate, were not performed worldwide
and are, therefore, not reported in the THAOS registry.
Thus, although they are of interest in this disease,35
evaluation of MR severity and LV systolic function was
limited. Not all echocardiography machines used were
able to measure strain by Doppler tissue imaging or two-
dimensional speckle-tracking, measurements may differ
between brands of device. This makes it difficult to cal-
culate a mean value.
Lastly, this study focused only on TTR amyloidosis,
whereas most of the signs described are also present in
AL cardiac amyloidosis. A diagnosis of AL cardiac amyl-
oidosis should be ruled out by other means, such as
demonstration of TTR amyloid deposition in a tissue
specimen. Future studies are needed comparing patients
with hypertensive heart disease and hypertrophic cardio-
myopathy with patients having ATTR amyloidosis to
determine sensitivity and specificity, and cut-off value of
each sign, to predict ATTR amyloidosis.
CONCLUSION
TTR cardiac amyloidosis should be suspected in the
presence of increased echocardiographic IVST, particu-
larly in patients >55 years of age, of male gender, with
normal SBP, increased thickness of RV free wall and
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valves, LAD enlargement and granular sparkling of the
myocardium. Female gender or absence of restrictive
pattern, or absence of low voltage or LV dysfunction,
should not rule out the possibility of cardiac ATTR.
ATTR genetic testing should be performed in patients
with suspected TTR cardiomyopathy, as the criteria
above are not specific and were present across the differ-
ent ATTR genotypes and in WT-ATTR. Further studies,
including control groups, are needed to determine the
specificity, sensitivity and cut-off values of the criteria
described in this study.
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